Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0699790 (
colon cancer
)
28,837
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Protein phosphatase 1 (PP1) is a major serine/threonine phosphatase that controls gene expression and cell cycle progression. Here we describe the characterization of a novel inhibitory molecule for PP1, human
inhibitor-5 of protein phosphatase 1
(
IPP5
). We find that
IPP5
, containing the PP1 inhibitory subunits, specifically interacts with the PP1 catalytic subunit and inhibits PP1 phosphatase activity. Furthermore, the mutation of Thr-40 within the inhibitory subunit of
IPP5
into Ala eliminates the phosphorylation of
IPP5
by protein kinase A and its inhibitor activity to PP1, whereas the mutation of Thr-40 within a truncated form of
IPP5
into Asp can serve as a dominant active form of
IPP5
in inhibiting PP1 activity. In
IPP5
-negative SW480 and
IPP5
-highly positive SW620 human
colon cancer
cells, we find that overexpression of
IPP5
promotes the growth and accelerates the G(1)-S transition of SW480 cells in a Thr-40-dependent manner, which could be reversed by downregulation of the PP1 expression. Moreover, silencing of
IPP5
inhibits the growth of SW620 cells both in vitro and in nude mice possibly by inducing G(0)/G(1) arrest but not by promoting apoptosis. According to its role in the promotion of cell cycle progression and cell growth,
IPP5
up-regulates the expression of cyclin E and the phosphorylated form of retinoblastoma protein. Our findings suggest that
IPP5
, by acting as an inhibitory molecule for PP1, can promote tumor cell growth and cell cycle progression, and may be a promising target in cancer therapeutics in
IPP5
-highly expressing tumor cells.
...
PMID:IPP5, a novel protein inhibitor of protein phosphatase 1, promotes G1/S progression in a Thr-40-dependent manner. 2575 Feb 61